Microbix Biosystems Inc. (TSX: MBX)
Health Care · Biotechnology · CA
CA$0.30
-3.23% today · +17.6% 1Y
Microbix Biosystems Inc. (TSX: MBX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.05M and employs 100 people.
Over the last twelve months the share price has gained 17.6%, trading between 0.21 and 0.33.
Tweenvest scores Microbix Biosystems Inc. across four factors: quality 66/100, value 58/100, growth 15/100. Its strongest factor is quality.
MBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.05M
- Revenue (TTM)
- $10.84M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- CA$0.33
- 52-week low
- CA$0.21
- Avg volume (3M)
- —
- Shares outstanding
- 136.97M
- Employees
- 100
- Next earnings
- —
About Microbix Biosystems Inc.
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
- ISIN
- CA59501P1045
- Founded
- 1988
- Listed since
- Aug 13, 1996
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cleo Diagnostics LtdASX: COV | $29.57M | AU$0.31 | -1.59% |
| Parataxis Korea, Inc.KOSDAQ: A288330 | $29.36M | ₩— | — |
| Medicenna Therapeutics Corp.TSX: MDNA | $29.36M | CA$0.45 | +3.45% |
| Quratis Inc.KOSDAQ: A348080 | $29.12M | ₩3,310.00 | -11.50% |
| CEL-SCI CorporationNYSEAM: CVM | $28.85M | $1.64 | +1.86% |
| TransCode Therapeutics, Inc.NasdaqCM: RNAZ | $28.78M | $1.70 | -8.60% |
| Amplia Therapeutics LimitedASX: ATX | $28.57M | AU$0.08 | -23.81% |
| NextCure, Inc.NasdaqGS: NXTC | $28.56M | $6.24 | -13.09% |
Figures last refreshed Oct 18, 2026.